AIM: To describe the frequency of neovascular age-related macular degeneration (nAMD) in second eyes of patients undergoing ranibizumab therapy in their first eye and to evaluate the patterns of optical coherence tomography (OCT) abnormalities in fellow eyes before nAMD. METHOD: Patients who developed choroidal neovascularization (CNV) in the second eye while on treatment for the first eye were identified. OCT scans of the second eyes, performed before the onset of CNV, were retrospectively examined and graded. Frequency of second eye involvement was estimated and patterns of progression of OCT abnormalities were described and classified. RESULTS: In all, 65 out of 749 consecutive patients required ranibizumab in their second eye for treatment-naïve nAMD over a 2-year period. The mean interval from commencement of ranibizumab in first eye to conversion in second eye was 12 months (2-35.5 months). There were three patterns of CNV development: group A (12%, n=8) had no OCT abnormalities in the second eye just before developing CNV; group B (38%, n=25) had no abnormalities at baseline but developed OCT changes more than one visit before conversion and group C (50%, n=32) had OCT changes from baseline, which did not progress until just before conversion. CONCLUSION: Patients with retinal pigment epithelial elevation without sub-retinal fluid on OCT in their fellow eyes have a high risk of progression to require therapy within a 2-year period. An anticipatory approach may be warranted, but a small group with completely normal OCT appearances can still develop lesions between visits.
AIM: To describe the frequency of neovascular age-related macular degeneration (nAMD) in second eyes of patients undergoing ranibizumab therapy in their first eye and to evaluate the patterns of optical coherence tomography (OCT) abnormalities in fellow eyes before nAMD. METHOD:Patients who developed choroidal neovascularization (CNV) in the second eye while on treatment for the first eye were identified. OCT scans of the second eyes, performed before the onset of CNV, were retrospectively examined and graded. Frequency of second eye involvement was estimated and patterns of progression of OCT abnormalities were described and classified. RESULTS: In all, 65 out of 749 consecutive patients required ranibizumab in their second eye for treatment-naïve nAMD over a 2-year period. The mean interval from commencement of ranibizumab in first eye to conversion in second eye was 12 months (2-35.5 months). There were three patterns of CNV development: group A (12%, n=8) had no OCT abnormalities in the second eye just before developing CNV; group B (38%, n=25) had no abnormalities at baseline but developed OCT changes more than one visit before conversion and group C (50%, n=32) had OCT changes from baseline, which did not progress until just before conversion. CONCLUSION:Patients with retinal pigment epithelial elevation without sub-retinal fluid on OCT in their fellow eyes have a high risk of progression to require therapy within a 2-year period. An anticipatory approach may be warranted, but a small group with completely normal OCT appearances can still develop lesions between visits.
Authors: Tien Y Wong; Tien Wong; Usha Chakravarthy; Ronald Klein; Paul Mitchell; Gergana Zlateva; Ronald Buggage; Kyle Fahrbach; Corey Probst; Isabella Sledge Journal: Ophthalmology Date: 2007-08-06 Impact factor: 12.079
Authors: Philip J Rosenfeld; David M Brown; Jeffrey S Heier; David S Boyer; Peter K Kaiser; Carol Y Chung; Robert Y Kim Journal: N Engl J Med Date: 2006-10-05 Impact factor: 91.245
Authors: Neil M Bressler; Tom S Chang; Ivan J Suñer; Jennifer T Fine; Chantal M Dolan; James Ward; Tsontcho Ianchulev Journal: Ophthalmology Date: 2010-03-02 Impact factor: 12.079
Authors: Panagiotis Malamos; Stefan Sacu; Michael Georgopoulos; Christopher Kiss; Christian Pruente; Ursula Schmidt-Erfurth Journal: Invest Ophthalmol Vis Sci Date: 2009-06-03 Impact factor: 4.799
Authors: Peter K Kaiser; David M Brown; Kang Zhang; Henry L Hudson; Frank G Holz; Howard Shapiro; Susan Schneider; Nisha R Acharya Journal: Am J Ophthalmol Date: 2007-10-22 Impact factor: 5.258
Authors: Carl D Regillo; David M Brown; Prema Abraham; Huibin Yue; Tsontcho Ianchulev; Susan Schneider; Naveed Shams Journal: Am J Ophthalmol Date: 2008-02 Impact factor: 5.258
Authors: Yasuo Yanagi; Aditi Mohla; Shu Yen Lee; Ranjana Mathur; Choi Mun Chan; Ian Yeo; Tien Yin Wong; Chui Ming Gemmy Cheung Journal: JAMA Ophthalmol Date: 2018-08-01 Impact factor: 7.389
Authors: Peter Maloca; Pascal W Hasler; Daniel Barthelmes; Patrik Arnold; Mooser Matthias; Hendrik P N Scholl; Heinrich Gerding; Justus Garweg; Tjebo Heeren; Konstantinos Balaskas; J Emanuel Ramos de Carvalho; Catherine Egan; Adnan Tufail; Sandrine A Zweifel Journal: Transl Vis Sci Technol Date: 2018-07-24 Impact factor: 3.283